Nycomed Imaging As

Nycomed Salutar, Inc.

Pangl Rongved

Jo Klaveness

Per Strande

Harald Dugstad

Lars Stubberud

Arne Berg

Roald Skurtveit

Klaes Golman

Ib Leunbach

Keith Redford

Unni Nordby Wiggen

Hanno Priebe

Jan Solberg

Goran Pettersson

Klaus D Krautwurst

Peter Leander

Torsten Alm En

Richard J Himmelsbach

Sook-Hui Kim

Per Antonius Foss

Wolfgang H Gunther

Ultrasound contrast agents having microbubbles of gas or a gas precursor encapsulated by non-proteinaceous crosslinked or polymerised amphiphilic moieties, e.g. in the form of micelles, exhibit good stability in vivo upon administration and may if desired incorporate biodegradable linkages so as to possess particular desired levels of biodegradability.

Microbubble-containing contrast agents having a non-proteinaceous

Novel extended polymer surfactants comprising a methoxy-terminated polyethylene glycol hydrophilic block acylated with a hydrophobic moiety comprising a chain of at least two fatty acid units, e.g. an acyloxyacyl group such as 16-hexadecanoyloxyhexadecanoyl, are useful in the preparation of polymer-based gas-containing contrast agents by emulsion techniques.

Contrast agents

There is provided a contrast medium composition comprising: (a) a first contrast agent comprising a physiologically tolerable manganese compound, a physiologically tolerable reducing compound containing an .alpha.-hydroxy ketone group, or salt thereof, having a manganese concentration of at least 0.3 mM or being in a dosage unit form containing at least 300 .mu.mol manganese, together with (b) a second contrast agent. Such compositions have been found to be particularly suited to imaging of the liver.

Contrast agents for MRI using a manganese compound and kojic acid

The present invention relates to contrast agents comprising water-soluble microbubble-generating carbohydrate microparticles in admixture with at least 10% w/w relative to the overall composition of a non-surface active material which is less water soluble than the carbohydrate. The contrast agents exhibit useful levels of contrast efficiency and/or stability and may be used in diagnostic applications such as ultrasound and MR imaging.

Contrast agents, consisting of carbohydrate particles

A method of crosslinking a crosslinkable protein or carbohydrate substrate to form a crosslinked substrate in which the crosslinking groups are biodegradable. The crosslinking groups may comprise methylene diacrylate and the substrate can be galactose.

Cross-linking agent

Polymeric surfactant-encapsulated microbubbles and their use in

Hydrazide derivatives of polyamides and their medical use as chelating

There is provided a contrast medium composition comprising: (a) a first contrast agent comprising a physiologically tolerable manganese compound together with an uptake promoter, having a manganese concentration of at least 0.3 mM or being in a dosage unit form containing at least 300 .mu.mol manganese, wherein the uptake promoter comprises a physiologically tolerable reducing compound containing an .alpha.-hydroxy ketone group or a physiologically tolerable acid containing .alpha.- and/or .beta.- hydroxy or amino groups, or a salt thereof, and/or vitamin D; together with (b) a second contrast agent. Such compositions are particularly suitable for imaging of the liver.

Composition and method of MRI using both a positive and a negative

Contrast agents comprising gas-containing or gas-generating

Contrast agents comprising gas-containing or gas-generating polymer microparticles and/or microballoons, in which the polymer is a biodegradable polymer containing units of formula

Contrast agents comprising gas-containing or gas-generating polymer

The present invention relates to contrast agents comprising microbubble-generating carbohydrate microparticles in admixture with an amphiphilic organic acid containing in excess of 20 carbon atoms. The contrast agents exhibit good stability and/or enhanced contrast effect and may be used in diagnostic applications such as ultrasound and MR imaging.

Contrast agents, consisting of galactose particles and an amphilic

The invention relates to the use as contrast enhancing agents in medical imaging, especially X-ray imaging, of multinuclear complexes, i.e. complexes, such as those of W202 (U20) 2, in which the complexed entity comprises at least two contrast enhancing atoms.

Multinuclear complexes for X-ray imaging

Heterocyclic chelating agents and salts thereof of formula I: ##STR1## wherein X represents a bond, O or S, or a group CHR.sup.1 or NR.sup.3 ; each R.sup.1 represents H, a group OR.sup.3 or NR.sup.3 R.sup.3, or an alkyl or alkoxyalkyl group optionally substituted by a hydroxyl group or by a group NR.sup.3 R.sup.3 or CON.sup.3 R.sup.3 ;

Diazine chelating agents for diagnostic imaging

This invention relates to ultrasound contrast agents in the form of microparticles comprising a biotolerable matrix (e.g. of a carbohydrate or an X-ray contrast agent) in association with a gas or a precursor therefor. The contrast agents are stabilized to enhance their in vivo stability and/or echogenicity by covalently modifying the structure of the matrix, e.g. to introduce crosslinking groups or to attach lipophilic groups and/or molecules. The covalent moieties may include biodegradable linkages to assist rapid subsequent elimination of the contrast agents from the system.

Growing community of inventors

Hellvik, Norway

Pangl Rongved